Du är här

2016-01-26

MorphoSys AG: MorphoSys Announces Clinical Milestone for Start of Bayer's Phase 2 Trial Designed to Support Registration of Anetumab Ravtansine

MorphoSys AG / MorphoSys Announces Clinical Milestone for Start of Bayer's
Phase 2 TrialDesigned to Support Registration of Anetumab Ravtansine .
Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is
solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today
announced that the company earned a milestone payment with Bayer's initiation
of a global phase 2 clinical study designed to support registration of
anetumab ravtansine (BAY 94-9343). Anetumab ravtansine, an antibody-drug
conjugate (ADC) targeting mesothelin, is a potential new treatment for
mesothelioma developed by Bayer using MorphoSys's HuCAL technology. Further
financial details were not disclosed.

"We are delighted to see our partner Bayer moving anetumab ravtansine into a
clinical study designed to support its registration in mesothelioma, an
indication with high medical need", commented Dr. Marlies Sproll, Chief
Scientific Officer of MorphoSys AG. "This is the fourth antibody derived from
the MorphoSys technology platform to advance into decisive stages of clinical
development. This again reflects the increasing maturity and value of the
MorphoSys pipeline comprising both proprietary and partnered programs."

MorphoSys's collaboration with Bayer has resulted in two clinical programs to
date. In total, MorphoSys's partnered and proprietary clinical pipeline
currently comprises 25 unique antibody molecules which are currently being
evaluated in more than 50 clinical trials.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 100 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,
visithttp://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies, The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties, Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated, MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned

For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications&IR

Alexandra Goller
Senior Manager Corporate Communications&IR

Jochen Orlowski
Associate Director Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

Media Release (PDF)
http://hugin.info/130295/R/1981085/725779.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire

HUG#1981085

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.